Home > Dermatology > AAD 2022 > Psoriasis: State of the Art > Novel developments in topical psoriasis therapy

Novel developments in topical psoriasis therapy

Presented By
Prof. April Armstrong, University of Southern California Keck School of Medicine, USA
Conference
AAD 2022
Trial
Phase 3, PSOARING; PSO-LONG
Topical therapy remains a mainstay of psoriasis management, especially in mild psoriasis. Today, proactive therapy is not only recommended in atopic dermatitis but also in psoriasis where it has demonstrated to prolong remission. “Most patients with psoriasis have mild disease, which might be treated with topical agents,” said Prof. April Armstrong (University of Southern California Keck School of Medicine, CA, USA). Topical steroids have been the workhorse of treating psoriasis for a long time. Today, new and more active topical treatments are on the horizon. The topical small molecule tapinarof is a modulator of the aryl hydrocarbon receptor, which is important for skin homeostasis. It lowers Th17 cytokines and oxidative stress and enables skin barrier normalisation. In 2 pivotal phase 3 trials (PSOARING 1 [NCT03956355] and PSOARING 2 [


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on